Strides Pharma Completes Pivot Path Stake Sale for ₹100 Cr

Strides Pharma Science Ltd has successfully completed the transaction for its partnership with Ascent Capital concerning Pivot Path. The deal involved selling a majority stake in Pivot Path to a consortium led by Ascent Capital and co-investor Vintage Classic for approximately ₹1,000 million. Strides has received ₹750 million upfront, with the remaining ₹250 million due on the first anniversary of the closing date. Following this transaction, Pivot Path is no longer a wholly-owned subsidiary and will be classified as an associate company from July 1, 2026.